Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...

It can now also be used as an add-on treatment in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Its original indication is as an add-on maintenance ...

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year ...

eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and has also shown efficacy in a phase 3 trial in chronic obstructive pulmonary disease (COPD).

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA ... Patients with other multisystem autoimmune diseases, such as eosinophilic granulomatous with polyangiitis, systemic lupus ...

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...